Purdue Pharma's Oxycontin reformulated to thwart abusers; U.S. Marshals seize misbranded Beehive products;

> A reformulated controlled-release Oxycontin, intended to prevent the opioid medication from being cut, broken, chewed, crushed or dissolved to release medication earlier than planned, has been approved by the FDA. Announcement

> The FDA sent U.S. Marshals to Beehive Botanicals in Haywood, WI, to seize misbranded and unapproved new drugs comprising consumer creams, capsules, tablets, gum, throat spray, and shampoos. Release

> Vaccine-maker Sanofi Pasteur is expanding its use of the Pertinence Suite Manufacturing Operations Management (MOM) software solution of Intercim, to European locations and North American sites. Release

> The U.K.-based Chemical Business Association has launched the Security Code, which requires a five-stage risk assessment, as part of its Responsible Care program. Release

> The Massachusetts Life Sciences Center has granted Worcester Polytechnic Institute $6.6 to build an 80,000-square-foot life sciences facility that will include a biomanufacturing education and training. Article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.